<DOC>
	<DOCNO>NCT00256711</DOCNO>
	<brief_summary>This randomize , open label , parallel group , multi-centre , phase II study progression free survival , compare oral ZD1839 ( IRESSA™ ) ( 250 mg tablet daily ) vinorelbine 30 mg/m2 infusion day 1 8 21-day cycle ) chemonaïve , elderly patient locally advance ( stage IIIB ) metastatic ( stage IV ) non-small cell lung cancer .</brief_summary>
	<brief_title>Phase II Iressa Versus Vinorelbine ( INVITE )</brief_title>
	<detailed_description />
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Vinorelbine</mesh_term>
	<mesh_term>Vinblastine</mesh_term>
	<mesh_term>Gefitinib</mesh_term>
	<criteria>Histologically confirm NSCLC willing provide paraffin embed tumour tissue NSCLC locally advance ( Stage IIIB ) metastatic ( stage IV ) disease , amenable curative surgery radiotherapy chemonaïve , life expectancy 12 week WHO Performance status &lt; = 2 Newly diagnose CNS metastases Less 4 week since completion radiotherapy persistence radiotherapy relate toxicity . Hypersensitivity ZD1839 intravenous vinorelbine Prior treatment EGFR inhibitors Other coexist malignancy ALT/AST &gt; 2.5 x ULRR ANC &lt; 2.0 x 10^9/L platelet &lt; 100 x 10^9/L</criteria>
	<gender>All</gender>
	<minimum_age>70 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2009</verification_date>
	<keyword>Locally advanced metastatic NSCLC .</keyword>
	<keyword>Stage IIIb Stage IV lung cancer</keyword>
</DOC>